Nature Communications (Sep 2019)
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
- Minsuh Kim,
- Hyemin Mun,
- Chang Oak Sung,
- Eun Jeong Cho,
- Hye-Joon Jeon,
- Sung-Min Chun,
- Da Jung Jung,
- Tae Hoon Shin,
- Gi Seok Jeong,
- Dong Kwan Kim,
- Eun Kyung Choi,
- Seong-Yun Jeong,
- Alison M. Taylor,
- Sejal Jain,
- Matthew Meyerson,
- Se Jin Jang
Affiliations
- Minsuh Kim
- Asan Center for Cancer Genome Discovery, Asan Institute for Life Sciences
- Hyemin Mun
- Asan Center for Cancer Genome Discovery, Asan Institute for Life Sciences
- Chang Oak Sung
- Asan Center for Cancer Genome Discovery, Asan Institute for Life Sciences
- Eun Jeong Cho
- Asan Center for Cancer Genome Discovery, Asan Institute for Life Sciences
- Hye-Joon Jeon
- Asan Center for Cancer Genome Discovery, Asan Institute for Life Sciences
- Sung-Min Chun
- Asan Center for Cancer Genome Discovery, Asan Institute for Life Sciences
- Da Jung Jung
- Biomedical Engineering Research Center, Asan Institute for Life Sciences
- Tae Hoon Shin
- Biomedical Engineering Research Center, Asan Institute for Life Sciences
- Gi Seok Jeong
- Biomedical Engineering Research Center, Asan Institute for Life Sciences
- Dong Kwan Kim
- Department of Thoracic Surgery, Asan Medical Center, University of Ulsan College of Medicine
- Eun Kyung Choi
- Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine
- Seong-Yun Jeong
- Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine
- Alison M. Taylor
- Department of Medical Oncology and Center for Cancer-Genome Discovery, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School
- Sejal Jain
- Department of Medical Oncology and Center for Cancer-Genome Discovery, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School
- Matthew Meyerson
- Department of Medical Oncology and Center for Cancer-Genome Discovery, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School
- Se Jin Jang
- Asan Center for Cancer Genome Discovery, Asan Institute for Life Sciences
- DOI
- https://doi.org/10.1038/s41467-019-11867-6
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 15
Abstract
The clinical efficacy of standard therapy in lung cancer is limited by high level of heterogeneity. Here, the authors report patient-derived lung cancer organoids from different histological subtypes and show them to faithfully recapitulate the histology, genomics, and drug responses of the primary lung tumours.
